Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients in the United States. It also develops INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug for the treatment of rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [03/24/2020 12:04 PDT] Insmed Incorporated (NASDAQ:INSM), Up By 100.00% ($13.63) From $13.630 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [03/24/2020 08:21 PDT] INSM Expected to Trade Up After Bullish Patterns Develop
• [03/12/2020 08:16 PDT] INSM SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [03/12/2020 07:58 PDT] INSM Expected to Trade Up After Bullish Patterns Develop
• [03/03/2020 07:58 PST] INSM Expected to Trade Up After Bullish Patterns Develop
• [02/25/2020 09:51 PST] Insmed Incorporated (NASDAQ:INSM), Down By 100.00% ($30.79) From $30.790 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [02/12/2020 07:37 PST] INSM Expected to Trade Down After Bearish Patterns Develop
• [02/06/2020 10:10 PST] Insmed Incorporated (NASDAQ:INSM), Up By 100.00% ($28.10) After BUYINS.NET SqueezeTrigger Report Released on Monday, February 3rd 2020 at a Price of $28.100.
• [02/05/2020 07:40 PST] INSM Expected to Trade Up After Bullish Patterns Develop